Cancer cocktail: new combo aims to tame tough tumors

NCT ID NCT00479128

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a combination of three drugs—bortezomib, gemcitabine, and doxorubicin—in people with advanced urothelial cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the highest safe dose of the two chemotherapy drugs when given with bortezomib. Researchers will also watch for any tumor shrinkage. About 80 participants are enrolled at M.D. Anderson Cancer Center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bortezomib (Velcade) combined with gemcitabine (Gemzar) and doxorubicin (Adriamycin)
What this could lead to: If successful, this could identify a safe dose of this drug combination that may help shrink tumors in people with advanced urothelial cancer or other solid tumors.
What could go wrong: This is a very early (Phase 1) trial with only 80 participants, so it is mainly about finding a safe dose, not proving effectiveness. The combination may cause significant side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SURGICALLY UNRESECTABLE UROTHELIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm stage IVb bladder cancer ureter cancer urethra cancer Urethral Neoplasms Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR URETHRAL CANCER

Contacts and locations

Locations

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.